MANE Veradermics (MANE) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001827635
Activist 13DForm 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
139
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $84.2K priced
What the filings say about MANE
Insiders, 180 days
-$103.1M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$140.2M
6 notices
Activist stakes (13D), 180 days
1 filing
Largest: 0.2% of the class
Veradermics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Veradermics, Inc insiders sold a net $103.1M of stock across 40 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 23.3% of the 2,957,937 shares held after it.
- 3 other insiders sold within 30 days.
- 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MONTANOVA CAPITAL, LLC sold about $74.1M of MANE on Aug 19, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.9% of the 461,033 shares held after it.
- 3 other insiders sold within 30 days.
- 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MONTANOVA CAPITAL, LLC sold about $6.4M of MANE on Aug 19, 2026; 3 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.1% of the 226,797 shares held after it.
- 3 other insiders sold within 30 days.
- 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Waldman Reid Alexander sold about $1.2M of MANE on Aug 17, 2026; 3 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.5% of the 201,563 shares held after it.
- 3 other insiders sold within 30 days.
- 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Waldman Reid Alexander sold about $2.7M of MANE on Aug 17, 2026; 3 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 15.8% of the 174,073 shares held after it.
- 3 other insiders sold within 30 days.
- 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Waldman Reid Alexander sold about $3.0M of MANE on Aug 17, 2026; 3 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.40 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$103.1M over 180 days
-$103.1M over 90 days
below 97% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
139 funds bought in last quarter
more than 80% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.1% of the float short (float per yahoo 2026-10-26) · 4.7 days to cover · settled 2026-09-30
more than 72% of Pharma & Biotech
The situation: each line is one rule over one dataset
Seven Fleet Master Fund LP disclosed a 5%+ stake (0.2%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MANE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+267.6%12M
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MANE: institutional holders (13F)
13F holdings, latest reported quarter
4,168,970 sh
$512.5M
3,204,981 sh
$394.0M
2,401,868 sh
$295.3M
2,000,000 sh
$245.9M
1,877,775 sh
$230.9M
Congress trades in MANE
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Seven Fleet Master Fund LP
Activist 13D · 2026-05-05
0.2%
Seven Fleet Capital Management LP
Activist 13D · 2026-05-05
0.2%
Seven Fleet Capital Management GP LLC
Activist 13D · 2026-05-05
0.2%
Brian Liu
Activist 13D · 2026-05-05
0.2%
Longitude Capital Partners V, LLC
Activist 13D · 2026-02-12
7.0%
MANE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Averill Madison Master Fund, Ltd.
Filed 2026-08-19
$6.4M
Averill Master Fund, Ltd.
Filed 2026-08-19
$74.1M
Timothy Durso
Filed 2026-08-17
$9.7M
Reid Alexander Waldman
Filed 2026-08-17
$15.0M
AMZL, LP
Filed 2026-08-12
$11.4M
MANE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
F/m Emerald Life Sciences Innovation ETF
$3.6M position · as of 2026-05-31
3.4%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$8.6M position · as of 2026-06-30
2.0%
Twin Oak Strategic Solutions ETF
$3.0M position · as of 2026-05-31
2.0%
PROFUND VP PHARMACEUTICALS
$225.3K position · as of 2026-06-30
2.0%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$265.2K position · as of 2026-07-31
1.3%
JPMorgan Small Cap Growth Fund
$32.4M position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
1 active
2
Phase 3
2 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $103.1M sold by insiders over 180 days, 139 funds added last quarter, $140.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MANE financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | |
|---|---|---|
| Operating income | -$72.3M | -$26.8M |
| Net income | -$70.0M | -$26.5M |
| EPS (diluted) | -111.91 | -37.05 |
| Operating cash flow | -$71.6M | -$23.7M |
| Cash | $21.8M | $53.1M |
SEC XBRL, fiscal years, as known on 2026-10-27
MANE Stock Sonar score 3/7 axes
Find similar shapesCompareMANE ranks highest on institutional and government (80th percentile) and risk and compliance (30th), and lowest on insider conviction (1st), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MANE filings, in plain words
Are Veradermics insiders buying or selling MANE?
In the 180 days to 2026-10-27, Veradermics insiders were net sellers, a net $103.1M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of MANE?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $140.2M of stock; the latest, by Averill Madison Master Fund, Ltd., was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-27, Veradermics insiders were net sellers of MANE, a net $103.1M across purchases and sales reported on Form 4 by 4 sellers. None of the 15 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $140.2M of stock. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 0.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
